# Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer

> **NCT02277093** · PHASE2 · TERMINATED · sponsor: **Washington University School of Medicine** · enrollment: 11 (actual)

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** Pacritinib

## Key facts

- **NCT ID:** NCT02277093
- **Lead sponsor:** Washington University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2015-09-22
- **Primary completion:** 2016-03-31
- **Final completion:** 2016-10-27
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** FDA issued a clinical hold as pacritinib had increased side effects
- **Last updated:** 2017-05-01

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02277093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02277093, "Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02277093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*